Novartis, PTC Therapeutics and Huntington's disease

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...
The findings suggest that beta-blockers and other drugs that help restore balance to the autonomic nervous system may have ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
A recent $1 billion deal between PTC Therapeutics and Novartis for a Huntington’s disease treatment highlights a growing interest in this sector, suggesting a similar valuation could be achievable ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
Common symptoms of Huntington's include uncontrolled movements like jerking and twitching, loss of coordination, difficulty ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...
The first patient has begun treatment on a global trial of a novel medication for Huntington's disease, led within the UK by ...